Trial Profile
Phase III trial of bevacizumab biosimilar (ONS-1045) in patients with cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Registrational; Therapeutic Use
- Sponsors Outlook Therapeutics
- 14 Feb 2018 According to an Oncobiologics media release, Company expects to initiate this trial in 2019, and submit application to FDA in 2021.
- 20 Apr 2015 New trial record
- 15 Apr 2015 This trial, the first in a global phase III programme, is expected to be initiated in the fourth quarter of 2015, after pharmacokinetic data from a pivotal pharmacokinetic study have been reported, according to an Oncobiologics media release.